Yiyao

Yiyao, a Chinese healthcare platform launched in 2015, aimed to revolutionize healthcare through an online-to-offline (O2O) model, raising a substantial $200M to connect patients with doctors, pharmacies, and services. Despite launching into a fragmented and ostensibly ripe Chinese healthcare market, the company ultimately failed due to a toxic combination of unsustainable unit economics and strategic misalignment. Yiyao struggled with patient expectations for free consultations, doctors' reluctance to engage outside established hospital systems, and regulatory ambiguity surrounding online prescriptions, leading to operational chaos and a massive burn rate. The core problem for Yiyao was its attempt to subsidize both supply (doctors) and demand (patients) in a market where patients expected free services. This approach led to brutal unit economics that its $200M funding, while significant, couldn't indefinitely sustain, especially against better-capitalized rivals like Ping An Good Doctor and Ali Health. Yiyao's hybrid model, neither a pure marketplace nor a fully integrated provider, left it vulnerable to these platform giants who could absorb losses and leverage healthcare as a loss-leader within their broader ecosystems. The company lacked the structural advantages and deep pockets necessary to compete in a winner-take-all market where customer acquisition and retention costs were exorbitant. Ultimately, Yiyao's collapse serves as a stark reminder that even in massive, underserved markets, capital alone cannot overcome fundamental business model flaws. Healthcare marketplaces, especially in complex regulatory environments like China, demand more than just a good product idea; they require deep understanding of economic incentives for all stakeholders, regulatory navigation, and often, an integrated ecosystem play. The company's failure illustrates the difficulty of scaling healthcare services without genuine willingness to pay from one side of the marketplace and clear value proposition for the other, while also highlighting the competitive pressure from established giants who can play a long game. The lesson for future ventures is that healthcare marketplaces need structural advantages beyond merely connecting users. Founders must consider ecosystem disadvantages and the ability of larger players to cross-subsidize. A more focused approach with clear monetization paths and sustainable unit economics, potentially targeting specific high-value segments or chronic conditions with outcome-based models, might have offered a more viable path forward compared to Yiyao's broad, O2O ambitions.